Red wine and components flavonoids inhibit UGT2B17 in vitro

Background The metabolism and excretion of the anabolic steroid testosterone occurs by glucuronidation to the conjugate testosterone glucuronide which is then excreted in urine. Alterations in UGT glucuronidation enzyme activity could alter the rate of testosterone excretion and thus its bioavailability. The aim of this study is to investigate if red wine, a common dietary substance, has an inhibitory effect on UGT2B17. Methods Testosterone glucuronidation was assayed using human UGT2B17 supersomes with quantification of unglucuronidated testosterone over time using HPLC with DAD detection. The selected red wine was analysed using HPLC and the inhibitory effects of the wine and phenolic components were tested independently in a screening assay. Further analyses were conducted for the strongest inhibitors at physiologically relevant concentrations. Control experiments were conducted to determine the effects of the ethanol on UGT2B17. Results Over the concentration range of 2 to 8% the red wine sample inhibited the glucuronidation of testosterone by up to 70% over 2 hours. The ethanol content had no significant effect. Three red wine phenolics, identified by HLPC analyses, also inhibited the enzyme by varying amounts in the order of quercetin (72%), caffeic acid (22%) and gallic acid (9%); using a ratio of phenolic:testosterone of 1:2.5. In contrast p-coumaric acid and chlorogenic acid had no effect on the UGT2B17. The most active phenolic was selected for a detailed study at physiologically relevant concentrations, and quercetin maintained inhibitory activity of 20% at 2 M despite a ten-fold excess of testosterone. Conclusion This study reports that in an in vitro supersome-based assay, the key steroid-metabolising enzyme UGT2B17 is inhibited by a number of phenolic dietary substances and therefore may reduce the rate of testosterone glucuronidation in vivo. These results highlight the potential interactions of a number of common dietary compounds on testosterone metabolism. Considering the variety of foodstuffs that contain flavonoids, it is feasible that diet can elevate levels of circulating testosterone through reduction in urinary excretion. These results warrant further investigation and extension to a human trial to delineate the healt

Sex differences in vascular endothelial function and health in humans: Impacts of exercise.

This brief review presents historical evidence for the purported impacts of male and female sex hormones on the vasculature in humans, including effects on macro- and micro-vascular function and health. Impacts of aging on hormonal changes and artery function are considered in the context of the menopause. Physiological data are presented alongside clinical outcomes from large trials, in an attempt to rationalise disparate findings along the bench-to-bedside continuum. Finally, the theoretical likelihood that exercise and hormone treatment may induce synergistic and/or additive vascular adaptations is developed in the context of recent laboratory studies that have compared male and female responses to training. Differences between men and women in terms of the impact of age and cardiorespiratory fitness on endothelial function are addressed. Ultimately, this review highlights the paucity of high quality and compelling evidence regarding the fundamental impact, in humans, of sex differences on arterial function and the moderating impacts of exercise on arterial function, adaptation and health at different ages in either sex. This article is protected by copyright. All rights reserved

Testosterone and prostate safety

Objective: To review the safety of testosterone (T) therapy with regard to the prostate, with special emphasis on the controversial association between testosterone and prostate cancer. Methods: We reviewed the existing scientific and medical literature pertaining to the impact of T treatment on the prostate. Results: No large-scale, long-term controlled studies of T therapy versus placebo have yet been performed to document prostate safety. However, there is a wealth of evidence from smaller clinical trials as well as population-based longitudinal studies that fails to demonstrate any signal suggesting that T therapy in hypogonadal adult men poses an increased risk of prostate cancer. New evidence indicates that exogenous T does not raise intraprostatic T or dihydrotestosterone concentrations. Indeed, there is accumulating evidence that low serum T is associated with increased risk of prostate cancer and that these cancers may have more worrisome aggressive clinical features. In addition, multiple studies have failed to show that T therapy causes worsening of voiding symptoms due to benign prostatic hyperplasia. Conclusions: Despite the long-held belief that T therapy may pose an increased risk of prostate cancer, the available evidence strongly suggests that T therapy is safe for the prostate. Given that the population at risk for hypogonadism overlaps with the population at risk for prostate cancer, it is strongly recommended that men undergoing T therapy undergo regular monitoring for prostate cancer.SCOPUS: ch.binfo:eu-repo/semantics/publishe